Foghorn Therapeutics Inc. (Nasdaq: FHTX) is making strides in the fight against serious diseases with the development of a groundbreaking new class of medicines designed to correct abnormal gene expression. The company recently announced an update on the FHD-609 program, which is aimed at treating synovial sarcoma and SMARCB1-deleted tumors. This impressive effort has the potential to revolutionize the way we approach treating these debilitating diseases.
Foghorn recently announced a pause in enrollment for its FHD-609 study, which was examining the effectiveness of FHD-609 in synovial sarcoma and SMARCB1-deleted tumors. This pause was due to a grade 4 QTc prolongation event in a synovial sarcoma patient at the second highest dose, prompting the Company to take safety measures and communicate them to the FDA and European regulatory authorities.
As a result, the FDA placed a partial clinical hold on the study in the United States, while allowing currently enrolled and benefiting patients to stay on therapy. Although the Company is not planning to pursue a dose expansion study independently at this time, it continues to ensure the safety of participating patients.
About Foghorn Therapeutics
Foghorn® Therapeutics Inc. is revolutionizing medicine by discovering and developing a unique class of treatments that target dependencies in the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control® platform, the Company is actively identifying and validating drug targets, with the aim of creating multiple product candidates in oncology. Foghorn’s pioneering approach is set to reshape the future of medical treatments.